Can a single drug stop transplant rejection? new trial hopes to find out

NCT ID NCT04572815

First seen Dec 12, 2025 · Last updated May 05, 2026 · Updated 26 times

Summary

This study tests whether the drug ustekinumab can prevent acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant from an unrelated donor for blood cancers. GVHD occurs when donor cells attack the patient's body. Ustekinumab aims to calm the immune system to reduce this risk. The trial involves 116 participants and compares ustekinumab to a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center,

    Duarte, California, 91010, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida, 33612, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.